Praxis Precision Medicines, Inc. Logo

Praxis Precision Medicines, Inc.

Developing therapies for CNS disorders using insights from genetic epilepsies.

PRAX | US

Overview

Corporate Details

ISIN(s):
US74006W2070
LEI:
Country:
United States of America
Address:
99 HIGH STREET, 30TH FLOOR, 2110 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) disorders. The company's core strategy involves translating insights from genetic epilepsies to treat conditions characterized by neuronal excitation-inhibition imbalance. Praxis's approach is guided by four principles: focusing on human genetics, utilizing translational tools for validation, applying patient-guided development, and pursuing efficient clinical pathways. Its developmental pipeline includes multiple clinical-stage assets and early-stage programs aimed at delivering treatments for patients with complex brain disorders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Praxis Precision Medicines, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Praxis Precision Medicines, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Praxis Precision Medicines, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea 341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea 456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG
Galderma Group AG Logo
A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.
Switzerland GALD
GALECTIN THERAPEUTICS INC Logo
Developing galectin-3 inhibitors for MASH cirrhosis, fibrosis, and cancer.
United States of America GALT
Galecto, Inc. Logo
Develops novel small molecule drugs targeting cancer and severe fibrotic diseases.
United States of America GLTO
Galmed Pharmaceuticals Ltd. Logo
Develops oral therapeutics for liver, metabolic, and inflammatory diseases like NASH.
United States of America GLMD
GC CELL CORPORATION Logo
Biotech firm offering cell/gene therapy CDMO services and developing immune cell cancer therapies.
South Korea 144510
Gelteq Ltd Logo
Ingestible gel platform for enhanced oral delivery of drugs & nutrients for human & animal health.
United States of America GELS

Talk to a Data Expert

Have a question? We'll get back to you promptly.